Telehealth firm eMed said on Thursday it has raised $200 million in its latest funding round, valuing the Miami, Florida-based company at more than $2 billion. Backed by seven-time Super Bowl champion Tom Brady, the company partners with employers and government payers to manage GLP-1 usage, a class of obesity and diabetes drugs whose cost burden has been a barrier to wider insurance coverage. Several telehealth platforms are competing for a slice of the booming GLP-1 weight-loss market, widely expected to generate $150 billion in annual…
Source link
Disclaimer
We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
